ANDA 90514, held by Pharmobedient. Trazodone Hydrochloride.
As of Nov 16, 2026, ANDA 90514 (Trazodone Hydrochloride), held by Pharmobedient, was first approved by FDA on Jun 2, 2009, with 4 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 2, 2009 | Original application | Approved | None posted |
| Trazodone Hydrochloride50MG · tablet;oral | Trazodone Hydrochloride | Discontinued |
| Trazodone Hydrochloride100MG · tablet;oral | Trazodone Hydrochloride | Discontinued |
| Trazodone Hydrochloride150MG · tablet;oral | Trazodone Hydrochloride | Discontinued |
| Trazodone Hydrochloride300MG · tablet;oral | Trazodone Hydrochloride | Discontinued |
| Jun 24, 2025 | Supplement 7Labeling · Standard review | Approved | None posted |
| May 18, 2020 | Supplement 6Labeling · Standard review | Approved | None posted |
| Jul 17, 2014 | Supplement 4Labeling · Standard review | Approved | None posted |
| Jul 1, 2014 | Supplement 3Labeling · Standard review | Approved | None posted |
| Jun 2, 2009 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters